Standard Chemical & Pharmaceutical Co. Ltd.

TWSE:1720 Stock Report

Market Cap: NT$11.1b

Standard Chemical & Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Standard Chemical & Pharmaceutical has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 12% per year. Standard Chemical & Pharmaceutical's return on equity is 13.7%, and it has net margins of 12.6%.

Key information

16.1%

Earnings growth rate

16.1%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate12.0%
Return on equity13.7%
Net Margin12.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Jul 29
Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

Jul 14
Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

Apr 13
If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Mar 14
A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Mar 01
Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Feb 16
Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

Feb 03
Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 19
Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Jan 04
Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

Dec 22
Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Dec 08
A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Nov 26
Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown

How Standard Chemical & Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:1720 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,7088481,287284
30 Jun 246,6118541,272286
31 Mar 246,3608771,225270
31 Dec 236,2408351,200266
30 Sep 236,2318481,209252
30 Jun 236,1358631,174246
31 Mar 236,1078531,151250
31 Dec 225,8518151,117252
30 Sep 225,5018131,034256
30 Jun 225,072734988249
31 Mar 224,740672970243
31 Dec 214,604707949242
30 Sep 214,489694980237
30 Jun 214,413649983239
31 Mar 214,372612973233
31 Dec 204,305524986227
30 Sep 204,219461962220
30 Jun 204,223455975224
31 Mar 204,125425979225
31 Dec 193,937376968226
30 Sep 193,905374981229
30 Jun 193,769383966217
31 Mar 193,656383955216
31 Dec 183,573374933225
30 Sep 183,480329927228
30 Jun 183,624366951236
31 Mar 183,702367942248
31 Dec 173,849363968240
30 Sep 173,898393942252
30 Jun 173,761347918248
31 Mar 173,725319935243
31 Dec 163,674340917241
30 Sep 163,635338931250
30 Jun 163,529323918247
31 Mar 163,374325876238
31 Dec 153,321348873239
30 Sep 153,280345890221
30 Jun 153,275349866233
31 Mar 153,304381853239
31 Dec 143,296374828243
30 Sep 143,203334803253
30 Jun 143,125292797243
31 Mar 143,069277823235

Quality Earnings: 1720 has high quality earnings.

Growing Profit Margin: 1720's current net profit margins (12.6%) are lower than last year (13.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1720's earnings have grown by 16.1% per year over the past 5 years.

Accelerating Growth: 1720's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1720 had negative earnings growth (-0.06%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).

Return on Equity

High ROE: 1720's Return on Equity (13.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 08:44
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Standard Chemical & Pharmaceutical Co. Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Qing Rong LinE.Sun Securities Investment Consulting Co. Ltd.
Regina LeeIBTS Investment Consulting Co., Ltd.
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.